Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study with the primary objective of identifying the maximum tolerated dose
(MTD) of FT516 using 3 dose-escalation strategies (number of doses and cell dose) for the
treatment of coronavirus disease 2019 (COVID-19). This study provides initial estimates of
safety and efficacy based on stable respiratory function, as well as, determining the
feasibility for full-scale studies designed both for efficacy and safety.